Investor Presentation, page-119

In there recent presentation the company spoke about the HDE filing for bile cancer in the US happening in recent quarter. They must be close to filing it and we should get feedback for this soon. If this is approved by the FDA then the company could be earning revenues from the US this year.

So much to look forward to as the company transitions to a viable commercial business able to generate revenue.

The SP does not represent its true potential and hence value but the flip side is that this Covid 19 crisis has allowed us all to accumulate at great prices.

IMHO it won’t be too long before we get back in the 20s and hopefully finally break that 27.5c ceiling towards the second half of this year to reach the brokers targets of 40c.

Did not think we would be at these prices post CE Mark hence the opportunity now.

Agree that the opportunity cost for holding this stock over the years has been unfortunately high but no point lamenting the mishaps of the past. That is history now.

I look forward to the next 6-12 months and beyond.